Regulatory Validation and ECHA Compliance
The reliability of our technology is backed by validated European registration dossiers (BPR).
ECHA Approved: Salveco’s technological platform is based on more than 260 formulas holding Marketing Authorizations (MAs), whose efficacy dossiers have been rigorously audited and validated by the ECHA (European Chemicals Agency).
Data Reliability: Each claim is based on certified inter-laboratory testing, guaranteeing total industrial reproducibility.
This regulatory approval process scientifically confirms the efficacy equivalence between our plant-based technology and conventional chemistry (Quats, Chlorine, Alcohol). By strictly meeting the same European validation standards, Salveco demonstrates that an optimized, low-impact formulation can substitute petrochemical active substances without any loss of biocidal performance.
Performance Audit: Spectrums and Contact Times (European Standards)
Salveco technology meets the most demanding medical and industrial standards. Below are the technical validation thresholds:
Bactericidal Activity: Gram+ and Gram- Targets
Validated standards: EN 1276, EN 13727, EN 16615, EN 13697, EN 1500, EN 1499
Examples of test strains: Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli (K12), Enterococcus hirae.
R&D Proof: Log 5 reduction (99.999%) achieved from 30 seconds under medical conditions and 1 minute for surface applications (PT2/PT4).
Yeasticidal Activity: Fungal Control
Validated standards: EN 13624 / EN 1650 / EN 16615 / EN 13697
Example of test strain: Candida albicans.
R&D Proof: Validation of yeasticidal activity from 30 seconds (PT1) and 2 minutes (PT2/PT4).
Virucidal Activity: Analysis of Viral Inactivation Unlike simple organic acids, the Salveco complex is validated on the most complex spectrums:
Validated standards: EN 14476 / EN 16777
Enveloped viruses (Vaccinia virus, Coronavirus, H1N1): Total inactivation from 30 seconds.
Non-enveloped (naked) viruses (Adenovirus, Norovirus, Poliovirus): Efficacy under development, first results obtained in surface disinfection.
Patented Exclusivity: The Signature of Disruptive Formulation Engineering
The Salveco patent is not merely legal protection; it is scientific proof of the uniqueness of our approach in specialty chemistry. Where the market limits itself to conventional organic acid blends, our laboratory has developed a proprietary technological platform that redefines the limits of plant-based biocides.
Differential Analysis: Salveco vs. Standard Organic Acids
The competitive advantage lies in optimizing the bioavailability of the active substance.
Analysis of an example of a commercial professional product based on standard lactic acid for surface disinfection:
Synergy Engineering: The core of the patent lies in the discovery of a molecular complex capable of maximizing the active substance’s bioavailability. This synergy lowers interfacial tensions and promotes transmembrane diffusion, guaranteeing full efficacy at drastically reduced lactic acid concentrations (up to 10 times lower than market standards).
| Parameters | Market Solution based on Lactic Acid(Surface Disinfection PT2/4) | Salveco Technology(Surface Disinfection PT2/4) |
| Active Concentration | 5% to 15% | 0.4% to 2% |
| Action Time | 5 minutes | 2 minutes |
| Bactericidal Spectrum | EN1276, EN13697 – 5 min | EN1276, EN13697 – From 2 minutes |
| Yeasticidal Spectrum | Non-existent | EN1650, EN13697 – 2 minutes |
| Virucidal Spectrum | Non-existent | EN14476, EN16777 (Enveloped Viruses) – 2 minutes |
| Contact Time | Long (> 5-10 min) | Flash (from 30 sec) |
| CLP Profile | Irritant / Corrosive | Unclassified / Safety Profile |
Unique on the Market: Providing a superior spectrum of efficacy (bacteria, yeasts, and viruses) within a faster action time (2 min for surfaces / 30 seconds for hands) compared to standard lactic acid solutions on the market (which generally cover only bacteria in 5 minutes), our patent remains an unparalleled solution today.
The audit of microbiological and regulatory data demonstrates that Salveco’s patented technology is no longer just an alternative, but the new benchmark standard for low-impact, high-performance disinfection. By overcoming the historical barrier of concentration, Salveco proves that it is possible to achieve medical-grade efficacy while radically simplifying the hazard profile of formulations.
Key Takeaways for Securing Strategic Portfolios:
Patent: By integrating Salveco’s patented technology, manufacturers align themselves with a robust intangible asset, guaranteeing a technological competitive advantage and long-term regulatory safety. This marks the transition from “endured” disinfection (corrosive and risky) to “controlled” disinfection driven by high-tech, bio-based science.
Institutional Validation: An efficacy equivalence certified by ECHA across more than 260 formulas, guaranteeing total compliance with the strictest European requirements.
Broad Spectrum of Activity: Microbial inactivation validated on the most complex strains (Virucidal EN 14476, Yeasticidal EN 16615) from 30 seconds of contact time.
Operational Neutrality: A “Human-Safe” technology that preserves substrate integrity and user health, while providing a major competitive edge in terms of corporate social responsibility and regulatory compliance.
By integrating Salveco technology, manufacturers ensure a sustainable technological transition capable of reconciling global health imperatives with a vision of chemistry that is safe for Humans and their environment.
